In the last trading session, 1.24 million shares of the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) were traded, and its beta was 2.85. Most recently the company’s share price was $22.00, and it changed around -$1.25 or -5.38% from the last close, which brings the market valuation of the company to $1.14B. FDMT currently trades at a discount to its 52-week high of $36.25, offering almost -64.77% off that amount. The share price’s 52-week low was $9.44, which indicates that the current value has risen by an impressive 57.09% since then. We note from 4D Molecular Therapeutics Inc’s average daily trading volume that its 3-month average coming to 554.83K.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
Instantly FDMT has showed a red trend with a performance of -5.38% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently up 8.59% year-to-date, but still down -7.56% over the last five days. On the other hand, 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is -12.52% down in the 30-day period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target as assigned by Wall Street analysts is $44.57, which translates to bulls needing to increase their stock price by 50.64% from its current value. Analyst projections state that FDMT is forecast to be at a low of $30 and a high of $63.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
4D Molecular Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 7.58 percent over the past six months and at a -15.50% annual growth rate that is well below the industry average of 13.20%. The year-over-year growth rate is expected to be -72.80%, down from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 1.44M in revenue for the current quarter. 7 analysts expect 4D Molecular Therapeutics Inc to make 690k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 850k and 20.2M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 69.40%. Forecasts for the next quarter put sales growth at -96.60%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -46.35%.
FDMT Dividends
4D Molecular Therapeutics Inc’s next quarterly earnings report is expected to be released in July.
